文献速递淋巴瘤

慢性淋巴细胞白血病(CLL)患者对结合型肺炎球菌疫苗(PCV13)的应答

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).
PubMed 文献 · Leukemia · 2020-06-17

该研究分析了112例慢性淋巴细胞白血病(CLL)患者接种13价结合型肺炎球菌疫苗(PCV13)后的抗体应答及结局,以ELISA检测的PC-IgG水平翻倍定义为免疫应答。仅9例(8%)产生应答,其中8例为初治患者,1例为一线伊布替尼治疗者;既往接受化学免疫治疗者无应答。年龄≥60岁、IgG水平<400 mg/L、既往治疗及疾病进展征象与较低应答率相关。

要点

  • 112例CLL患者接种PCV13后仅9例(8%)产生免疫应答,初治患者8例,一线伊布替尼治疗者1例。
  • 既往化学免疫治疗者无应答;年龄≥60岁、IgG<400 mg/L、既往治疗及疾病进展征象与低应答率相关。
  • 有疾病进展临床征象、既往肺炎及TP53异常者无肺炎生存期显著缩短。

核心结论

  • 结果提示,对于早期、稳定且具备更好有效免疫应答资源的CLL患者,应在诊断时提供疫苗接种。

研究设计与样本

  • 分析了112例接受13价结合型肺炎球菌疫苗(PCV13)的CLL患者,以ELISA检测的PC-IgG水平翻倍定义免疫应答。
  • 患者中位年龄68岁,23.2% IgG水平≤400 mg/L,6.3%为进展性疾病,52%为IGHV未突变。
  • 22例(19.6%)为初治患者,90例(80.4%)为既往治疗患者(40.2%接受一线化学免疫治疗;伊布替尼一线/进展线分别为9.8%/21.4%;艾德拉尼进展线8.9%)。

主要发现

  • 9例(8%)患者产生免疫应答,其中8例为初治患者,1例为一线伊布替尼治疗者;既往接受化学免疫治疗者中未观察到应答。
  • 年龄≥60岁(p=0.007)、IgG水平<400 mg/L(p<0.0001)、既往治疗(p<0.0001)及疾病进展征象(p=0.04)与较低应答率相关。
  • 有疾病进展临床征象(HR 8.39)、既往肺炎(HR 7.03)及TP53异常(HR 2.91)的患者无肺炎生存期显著缩短。

临床怎么用

  • 作者认为,对于早期、稳定且具备更好有效免疫应答资源的CLL患者,应在诊断时提供疫苗接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pneumococcal (PC) vaccination is recommended for patients with chronic lymphocytic leukemia (CLL). However, response to vaccines has been investigated in a small series of CLL patients. We analyzed the antibody response and outcomes of 112 CLL patients who received the 13-valent pneumococcal conjugate vaccine (PCV13). An immune response was defined by a twofold increase in the PC-IgG levels assessed by ELISA. The median age of patients was 68 years, 23.2% showed IgG levels ≤ 400 mg/L, 6.3% progressive disease, 52% unmutated IGHV. Twenty-two (19.6%) patients were treatment-naïve and 90 (80.4%) previously treated (40.2% front-line chemoimmunotherapy; ibrutinib first/advanced-line, 9.8%/21.4%; idelalisib advanced-line, 8.9%). Nine (8%) patients developed an immune response, eight treatment-naive, and one on front-line ibrutinib. No responses were observed in patients previously treated with chemoimmunotherapy. Age ≥ 60 years (p = 0.007), IgG levels < 400 mg/L (p < 0.0001), prior treatment (p < 0.0001), and signs of disease progression (p = 0.04) were associated with a lower response rate. Pneumonia-free survival was significantly shorter in patients with clinical signs of progressive disease (HR, 8.39), prior pneumonia (HR, 7.03), and TP53 disruption (HR, 2.91). In conclusion, our results suggest that vaccination should be offered at diagnosis to CLL patients with early stage and stable disease who have better resources for an effective immune response.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2020. PMID: 32555297. doi:10.1038/s41375-020-0884-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。